Neuberger Berman Group LLC Has $82,814,000 Position in Cantel Medical Corp. (CMN)
Neuberger Berman Group LLC increased its stake in Cantel Medical Corp. (NYSE:CMN) by 11.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,061,984 shares of the company’s stock after buying an additional 109,230 shares during the period. Neuberger Berman Group LLC’s holdings in Cantel Medical Corp. were worth $82,814,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of CMN. Vanguard Group Inc. raised its stake in Cantel Medical Corp. by 3.1% in the second quarter. Vanguard Group Inc. now owns 2,762,913 shares of the company’s stock valued at $189,894,000 after buying an additional 84,162 shares in the last quarter. BlackRock Fund Advisors raised its stake in Cantel Medical Corp. by 5.9% in the second quarter. BlackRock Fund Advisors now owns 2,414,895 shares of the company’s stock valued at $165,976,000 after buying an additional 135,506 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Cantel Medical Corp. by 4.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 907,203 shares of the company’s stock valued at $62,352,000 after buying an additional 37,305 shares in the last quarter. Wells Fargo & Company MN raised its stake in Cantel Medical Corp. by 497.6% in the third quarter. Wells Fargo & Company MN now owns 803,444 shares of the company’s stock valued at $62,652,000 after buying an additional 668,993 shares in the last quarter. Finally, State Street Corp raised its stake in Cantel Medical Corp. by 4.6% in the second quarter. State Street Corp now owns 730,775 shares of the company’s stock valued at $50,225,000 after buying an additional 32,338 shares in the last quarter. Institutional investors own 82.99% of the company’s stock.
Shares of Cantel Medical Corp. (NYSE:CMN) opened at 81.01 on Tuesday. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of 56.34 and a beta of 1.41. Cantel Medical Corp. has a 12 month low of $55.01 and a 12 month high of $82.80. The stock’s 50 day moving average is $75.11 and its 200 day moving average is $72.52.
Cantel Medical Corp. (NYSE:CMN) last posted its quarterly earnings results on Thursday, September 29th. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.11. Cantel Medical Corp. had a net margin of 9.02% and a return on equity of 16.70%. The company had revenue of $179 million for the quarter. During the same quarter in the previous year, the business posted $0.39 earnings per share. The company’s revenue for the quarter was up 18.3% on a year-over-year basis. Equities research analysts forecast that Cantel Medical Corp. will post $1.96 earnings per share for the current fiscal year.
The business also recently declared a semiannual dividend, which will be paid on Tuesday, January 31st. Stockholders of record on Tuesday, January 17th will be paid a $0.07 dividend. This is an increase from Cantel Medical Corp.’s previous semiannual dividend of $0.06. This represents a dividend yield of 0.18%. The ex-dividend date is Thursday, January 12th. Cantel Medical Corp.’s dividend payout ratio (DPR) is presently 8.33%.
TRADEMARK VIOLATION WARNING: “Neuberger Berman Group LLC Has $82,814,000 Position in Cantel Medical Corp. (CMN)” was first published by Financial Market News and is owned by of Financial Market News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at http://www.financial-market-news.com/neuberger-berman-group-llc-has-82814000-position-in-cantel-medical-corp-cmn/1208362/.
Several analysts have issued reports on CMN shares. Benchmark Co. set a $83.00 price target on shares of Cantel Medical Corp. and gave the stock a “buy” rating in a research report on Saturday, October 1st. Needham & Company LLC started coverage on shares of Cantel Medical Corp. in a research report on Wednesday, August 24th. They issued a “hold” rating on the stock.
In related news, CAO Steven C. Anaya sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $77.07, for a total value of $423,885.00. Following the completion of the transaction, the chief accounting officer now owns 48,132 shares in the company, valued at approximately $3,709,533.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Charles M. Diker sold 14,897 shares of the firm’s stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $78.76, for a total transaction of $1,173,287.72. Following the completion of the transaction, the chairman now owns 3,190,111 shares of the company’s stock, valued at approximately $251,253,142.36. The disclosure for this sale can be found here. 15.30% of the stock is currently owned by insiders.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Want to see what other hedge funds are holding CMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMN).
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.